SI2768859T1 - Antagonisti il17c za zdravljenje inflamatornih motenj - Google Patents
Antagonisti il17c za zdravljenje inflamatornih motenj Download PDFInfo
- Publication number
- SI2768859T1 SI2768859T1 SI201231302T SI201231302T SI2768859T1 SI 2768859 T1 SI2768859 T1 SI 2768859T1 SI 201231302 T SI201231302 T SI 201231302T SI 201231302 T SI201231302 T SI 201231302T SI 2768859 T1 SI2768859 T1 SI 2768859T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- antibody
- il17c
- lcdr3
- lcdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (7)
1. Izolirano protitelo ali fragment protitelesa, specifičen za IL17C, za uporabo pri zdravljenju vnetne motnje, kjer je omenjena inflamatorna motnja pljučno vnetje, revmatoidni artritis in/ali kronična obstruktivna pljučna bolezen (COPD), kjer IL17C sestoji iz aminokislin SEQ. ID No.: 181 in pri čemer omenjeno protitelo blokira vezavo IL17C na IL17RE.
2. Izolirano protitelo ali fragment protitelesa, specifično za IL17C, za uporabo po zahtevku 1, kjer navedeno protitelo ali fragment protitelesa, prekrižno-tekmuje s protitelesom ali fragmentom protitelesa, ki obsega 6 CDR, definiranih po Kabat-u, ki je izbran izmed protitelesa ali fragmenta protitelesa, ki obsega: HCDR1 Seq. ID: 1, HCDR2 Seq. ID: 2, HCDR3 Seq. ID: 3, LCDR1 Seq. ID:
3. Izolirano protitelo ali fragment protitelesa, specifično za IL17C, za uporabo po zahtevku 1 ali 2, kjer je navedeno protitelo ali njegov fragment monoklonsko protitelo.
4. Protitelo ali fragment protitelesa, specifičen za IL17C, za uporabo po zahtevku 3, kjer navedeno protitelo ali fragment protitelesa je humano, humanizirano ali himerno protitelo ali fragment protitelesa.
4, LCDR2 Seq. ID: 5 in LCDR3 Seq. ID: 6 (MOR12740), ali HCDR1 Seq. ID: 31, HCDR2 Seq. ID: 32, HCDR3 Seq. ID: 33, LCDR1 Seq. ID: 34, LCDR2 Seq. ID: 35 in LCDR3 Seq. ID: 36 (MOR12743), ali HCDR1 Seq. ID: 41, HCDR2 Seq. ID: 42, HCDR3 Seq. ID: 43, LCDR1 Seq. ID: 44, LCDR2 Seq. ID: 45 in LCDR3 Seq. ID: 46 (MOR12744), ali HCDR1 Seq. ID: 51, HCDR2 Seq. ID: 52, HCDR3 Seq. ID: 53, LCDR1 Seq. ID: 54, LCDR2 Seq. ID: 55 in LCDR3 Seq. ID: 56 (MOR12745), ali HCDR1 Seq. ID: 61, HCDR2 Seq. ID: 62, HCDR3 Seq. ID: 63, LCDR1 Seq. ID: 64, LCDR2 Seq. ID: 65 in LCDR3 Seq. ID: 66 (MOR12746), ali HCDR1 Seq. ID: 71, HCDR2 Seq. ID: 72, HCDR3 Seq. ID: 73, LCDR1 Seq. ID: 74, LCDR2 Seq. ID: 75 in LCDR3 Seq. ID: 76 (MOR12751), ali HCDR1 Seq. ID: 91, HCDR2 Seq. ID: 92, HCDR3 Seq. ID: 93, LCDR1 Seq. ID: 94, LCDR2 Seq. ID: 95 in LCDR3 Seq. ID: 96 (MOR12754), ali HCDR1 Seq. ID: 141, HCDR2 Seq. ID: 142, HCDR3 Seq. ID: 143, LCDR1 Seq. ID: 144, LCDR2 Seq. ID: 145 in LCDR3 Seq. ID: 146 (MOR12759), ali HCDR1 Seq. ID: 151, HCDR2 Seq. ID: 152, HCDR3 Seq. ID: 153, LCDR1 Seq. ID: 154, LCDR2 Seq. ID: 155 in LCDR3 Seq. ID: 156 (MOR12760), ali HCDR1 Seq. ID: 161, HCDR2 Seq. ID: 162, HCDR3 Seq. ID: 163, LCDR1 Seq. ID: 164, LCDR2 Seq. ID: 165 in LCDR3 Seq. ID: 166 (MOR12761), ali HCDR1 Seq. ID: 171, HCDR2 Seq. ID: 172, HCDR3 Seq. ID: 173, LCDR1 Seq. ID: 174, LCDR2 Seq. ID: 175 in an LCDR3 oSeq. ID: 176 (MOR12762).
5. Protitelo ali fragment protitelesa, specifičen za IL17C, za uporabo po zahtevku 3, kjer navedeno protitelo ali fragment protitelesa obsega konstantno regijo humane težke verige in konstantno regijo humane lahke verige.
6. Protitelo ali fragment protitelesa, specifičen za IL17C za uporabo po zahtevku 3, kjer je navedeno protitelo izotip IgG.
7. Protitelo ali protitelesni fragment, specifičen za IL17C, za uporabo po zahtevku 3, kjer je omenjeni fragment protitelesa izbran iz skupine, ki jo sestavljajo Fab, F(ab2)', F(ab)2', scFV.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161548744P | 2011-10-19 | 2011-10-19 | |
EP11185763 | 2011-10-19 | ||
PCT/EP2012/070736 WO2013057241A1 (en) | 2011-10-19 | 2012-10-19 | Antagonists of il17c for the treatment of inflammatory disorders |
EP12775247.5A EP2768859B1 (en) | 2011-10-19 | 2012-10-19 | Antagonists of il17c for the treatment of inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2768859T1 true SI2768859T1 (sl) | 2018-06-29 |
Family
ID=48140378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231302T SI2768859T1 (sl) | 2011-10-19 | 2012-10-19 | Antagonisti il17c za zdravljenje inflamatornih motenj |
Country Status (21)
Country | Link |
---|---|
US (2) | US20140243506A1 (sl) |
EP (2) | EP2768859B1 (sl) |
JP (1) | JP2014530836A (sl) |
CN (1) | CN103974976A (sl) |
AU (1) | AU2012324895B2 (sl) |
CA (1) | CA2852145C (sl) |
CY (1) | CY1120219T1 (sl) |
DK (1) | DK2768859T3 (sl) |
ES (1) | ES2669984T3 (sl) |
HR (1) | HRP20180776T1 (sl) |
HU (1) | HUE037087T2 (sl) |
LT (1) | LT2768859T (sl) |
ME (1) | ME03073B (sl) |
MX (1) | MX360710B (sl) |
PL (1) | PL2768859T3 (sl) |
PT (1) | PT2768859T (sl) |
RS (1) | RS57209B1 (sl) |
SG (1) | SG11201401202YA (sl) |
SI (1) | SI2768859T1 (sl) |
TR (1) | TR201807056T4 (sl) |
WO (1) | WO2013057241A1 (sl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2724322C (en) | 2008-05-14 | 2019-07-16 | Dermtech International | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
TW201307385A (zh) * | 2010-10-25 | 2013-02-16 | Genentech Inc | 胃腸炎症和銀屑病以及哮喘的治療 |
AU2015367684A1 (en) * | 2014-12-15 | 2017-07-06 | Galapagos Nv | Antibodies for IL-17C |
AU2016335017A1 (en) | 2015-10-05 | 2018-03-29 | Galapagos Nv | Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis |
US20190048071A1 (en) * | 2016-02-19 | 2019-02-14 | Morphosys Ag | Antibodies for il-17c |
CA3022915A1 (en) * | 2016-05-03 | 2017-11-09 | The Scripps Research Institute | Trkb agonist antibodies for treating neurodegenerative disorders |
TW201919698A (zh) | 2017-09-25 | 2019-06-01 | 德商莫菲西斯公司 | 異位性皮炎之治療 |
EP3752645A4 (en) | 2018-02-14 | 2022-04-13 | Dermtech, Inc. | NEW GENE CLASSIFIERS AND THEIR USES IN NON-MELANOMA SKIN CANCERS |
GB201803563D0 (en) | 2018-03-06 | 2018-04-18 | Galapagos Nv | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases |
KR20210031640A (ko) | 2018-05-09 | 2021-03-22 | 덤테크, 인크. | 신규한 유전자 분류자 및 자가면역 질환에서의 이의 용도 |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
KR20210087891A (ko) * | 2019-12-30 | 2021-07-13 | 경상국립대학교병원 | 박테리아 감염증 예방 또는 치료용 약학 조성물 |
CN112795637A (zh) * | 2021-01-08 | 2021-05-14 | 孙洪臣 | 靶向il-17c的抑制剂在治疗炎症相关慢性肾脏疾病中的用途 |
WO2022204375A1 (en) * | 2021-03-25 | 2022-09-29 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
EP2333069A3 (en) | 1998-05-15 | 2011-09-14 | Genentech, Inc. | Therapeutic uses of IL-17 homologous polypeptides |
DK1144607T5 (da) | 1999-07-20 | 2009-10-05 | Morphosys Ag | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger |
ES2379101T3 (es) * | 1999-12-23 | 2012-04-20 | Genentech, Inc. | Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos |
US20040197306A1 (en) | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
EA200700823A1 (ru) * | 2004-10-18 | 2008-02-28 | Займодженетикс, Инк., Сша | Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении |
US20070129302A1 (en) * | 2005-10-18 | 2007-06-07 | Zeren Gao | Il-17c antagonists and methods of using the same |
CA2666842A1 (en) * | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
CN102027011B (zh) * | 2007-12-07 | 2014-09-03 | 津莫吉尼蒂克斯公司 | 抗人il-21单克隆抗体 |
WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
AU2010303166A1 (en) * | 2009-10-10 | 2012-05-24 | Eleven Biotherapeutics, Inc. | IL-17 family cytokine compositions and uses |
TW201307385A (zh) * | 2010-10-25 | 2013-02-16 | Genentech Inc | 胃腸炎症和銀屑病以及哮喘的治療 |
US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
-
2012
- 2012-10-19 ES ES12775247.5T patent/ES2669984T3/es active Active
- 2012-10-19 LT LTEP12775247.5T patent/LT2768859T/lt unknown
- 2012-10-19 ME MEP-2018-135A patent/ME03073B/me unknown
- 2012-10-19 EP EP12775247.5A patent/EP2768859B1/en active Active
- 2012-10-19 PT PT127752475T patent/PT2768859T/pt unknown
- 2012-10-19 AU AU2012324895A patent/AU2012324895B2/en active Active
- 2012-10-19 EP EP18157106.8A patent/EP3360897A1/en not_active Withdrawn
- 2012-10-19 RS RS20180567A patent/RS57209B1/sr unknown
- 2012-10-19 DK DK12775247.5T patent/DK2768859T3/en active
- 2012-10-19 TR TR2018/07056T patent/TR201807056T4/tr unknown
- 2012-10-19 CN CN201280051378.3A patent/CN103974976A/zh active Pending
- 2012-10-19 WO PCT/EP2012/070736 patent/WO2013057241A1/en active Application Filing
- 2012-10-19 SG SG11201401202YA patent/SG11201401202YA/en unknown
- 2012-10-19 HU HUE12775247A patent/HUE037087T2/hu unknown
- 2012-10-19 PL PL12775247T patent/PL2768859T3/pl unknown
- 2012-10-19 SI SI201231302T patent/SI2768859T1/sl unknown
- 2012-10-19 JP JP2014536248A patent/JP2014530836A/ja active Pending
- 2012-10-19 US US14/351,162 patent/US20140243506A1/en not_active Abandoned
- 2012-10-19 MX MX2014004662A patent/MX360710B/es active IP Right Grant
- 2012-10-19 CA CA2852145A patent/CA2852145C/en active Active
-
2018
- 2018-05-16 CY CY20181100504T patent/CY1120219T1/el unknown
- 2018-05-18 HR HRP20180776TT patent/HRP20180776T1/hr unknown
- 2018-11-08 US US16/184,390 patent/US10815297B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX360710B (es) | 2018-11-14 |
WO2013057241A1 (en) | 2013-04-25 |
US20190062422A1 (en) | 2019-02-28 |
HRP20180776T1 (hr) | 2018-08-10 |
TR201807056T4 (tr) | 2018-06-21 |
EP3360897A1 (en) | 2018-08-15 |
ME03073B (me) | 2019-01-20 |
RS57209B1 (sr) | 2018-07-31 |
US10815297B2 (en) | 2020-10-27 |
DK2768859T3 (en) | 2018-06-06 |
LT2768859T (lt) | 2018-06-11 |
CA2852145C (en) | 2021-01-12 |
AU2012324895B2 (en) | 2017-03-16 |
SG11201401202YA (en) | 2014-06-27 |
US20140243506A1 (en) | 2014-08-28 |
HUE037087T2 (hu) | 2018-08-28 |
MX2014004662A (es) | 2015-06-02 |
AU2012324895A1 (en) | 2014-04-17 |
PT2768859T (pt) | 2018-05-23 |
PL2768859T3 (pl) | 2018-07-31 |
CN103974976A (zh) | 2014-08-06 |
CA2852145A1 (en) | 2013-04-25 |
JP2014530836A (ja) | 2014-11-20 |
EP2768859A1 (en) | 2014-08-27 |
NZ623289A (en) | 2015-12-24 |
ES2669984T3 (es) | 2018-05-29 |
CY1120219T1 (el) | 2018-12-12 |
EP2768859B1 (en) | 2018-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2768859T1 (sl) | Antagonisti il17c za zdravljenje inflamatornih motenj | |
NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
JP2022177090A5 (sl) | ||
NZ703035A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
LTPA2017038I1 (lt) | Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių | |
HRP20171992T1 (hr) | Protutijela protiv cgrp | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
RU2017128882A (ru) | Антитела к биотину и способы их применения | |
NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
RS54685B1 (en) | ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES | |
JP2015535828A5 (sl) | ||
NZ603529A (en) | Antibodies to human gdf8 | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
JP2013198490A5 (sl) | ||
RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
RS52592B (en) | ANTI-HEPCIDINE ANTIBODIES AND THEIR USE | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos |